

# 2014 TCTAP

## Wrap-Up Interview

# Invasive Imaging

**Moderator**

**Gary S. Mintz**

**Interviewees**

**Takashi Akasaka, Akiko Maehara, Evelyn Regar**

# Issues in Brief

- **VH-IVUS: PROSPECT/VIVA/ATHEROREMO Study**
- **OCT: OCT guided PCI**
- **NIRS: Current Status and Ongoing Studies**
- **IVUS: Attenuated Plaque**


# Definition of Vulnerable Plaque

## Major criteria

- Active Inflammation
- Thin Cap with Large Lipid Core
- Endothelial Denudation with Superficial Platelet Aggregation
- Fissured Plaque
- Stenosis >90%

# PROSPECT

## Correlates of Non Culprit Lesion Related Events




# VIVA Study

**167 pts; 3-vessel VH-IVUS; 625 days**


18 MACE (death [2], MI [2] or revasc [14]) in 16 pts  
from 19 lesions (13 nonculprit lesions and 6 culprit lesions)



**Univariate predictors of non-culprit MACE**

## Grayscale IVUS characteristics



## VH-IVUS lesion classification





- A VH-TCFA (present 10.8% vs. absent 5.6%; adjusted HR: 1.98,  $P=0.026$ ) and a plaque burden  $\geq 70\%$  (present 16.2% vs. absent 5.5%; adjusted HR: 2.90,  $P<0.001$ ), but not the presence of lesions with an MLA  $\leq 4.0$  mm $^2$ , were independently associated with MACE.
- Risk for MACE was further increased if the VH-TCFA lesions had a MLA  $\leq 4.0$  mm $^2$ , plaque burden  $\geq 70\%$ , or a combination of these three characteristics
- VH-TCFAs with a plaque burden  $\geq 70\%$  were associated with a higher MACE rate both in the first 6 months ( $P=0.011$ ) and after 6 months ( $P<0.001$ ), while smaller TCFA lesions were only associated with a higher MACE rate after 6 months ( $P=0.033$ )

# Which One is Better?

## IVUS guided PCI

### ADAPT DES

Witzenbichler et al. Circulation 2014;129:463-70

### 4 Meta-Analysis

Zhang et al. Eurointervention 2012;8:855-65

Kersy C et al. Int J Cardiol 2013;170:54-63

Jang et al. JACC Cardiovasc Interv  
2014;7:233-43

Ahn et al. Am J Cardiol 2014;113:1338-47

## OCT guided PCI

### CLI-OPCI

Prati F et al. EuroIntervention 2012;8:823-9

### OCT vs IVUS guided PCI

Habara et al.


Circ Cardiovasc Interv. 2012;5:193-201

# Four meta-analyses have assessed IVUS vs angiography-guided DES implantation



Reference	Yr	RCT	Non-RCT	Pts	HR (p-values)					
					MACE	Death	MI	ST	TLR	TVR
Zhang et al Euroin tervention	2012	1	10	19,619	0.87 (p=0.008)	0.59 (p<0.001)	0.82 (p=0.13)	0.58 (p<0.001)	0.90 (p=0.3)	0.90 (p=0.2)
Propensity score m atched sub-analysis			6	5,300	0.86 (p=0.06)	0.73 (p=0.04)	0.63 (p=0.01)	0.57 (p=0.004)	0.85 (p=0.3)	0.94 (p=0.6)
Klersy et al Int J Cardiol	2013	3	9	18,707	0.80 (p<0.001)	0.60 (p<0.001)	0.59 (p=0.001)	0.58 (p=0.007)	0.95 (p=0.8)	
Jang et al. JACC Cardiovasc Interv	On-line	3	12	24,869	0.79 (p=0.001)	0.64 (p<0.001)	0.57 (p<0.001)	0.59 (p=0.002)	0.76 (p=0.01)	0.81 (p=0.01)
Propensity score ma tched sub-analysis			9	13,545	0.79 (p=0.01)	0.58 (p=0.01)	0.56 (p=0.04)	0.52 (p=0.004)	0.85 (p=0.3)	0.93 (p=0.3)
Ahn et al. Am J Ca rdiol	In press	3	14	26,503	0.74 (p<0.001)	0.61 (p<0.001)	0.57 (p<0.001)	0.59 (p<0.001)	0.81 (p=0.046)	0.82 (p=0.022)



# MACE (Definite/Probable ST, Cardiac Death, MI)



**Two year follow-up data from ADAPT-DES (3361 pts treated with IVUS-guidance vs 5221 pts treated with angiographic guidance)**



# Comparison of pts undergoing PCI with “OCT guidance” vs angiographic guidance at three high-OCT-volume Italian centers: CLI-OPCI Study

One year outcomes	OCT	Angiography	p
#	335	335	
Death	3.3%	6.9%	0.035
Cardiac death	1.2%	4.5%	0.010
MI	5.4%	8.7%	0.096
TLR	3.3%	3.3%	1
Definite ST	0.3%	0.6%	0.6
Cardiac death/MI	6.6%	13.0%	0.006
Cardiac death/MI or repeat revascularization*	9.6%	15.1%	0.034

**\*Even after accounting for baseline and procedural  
differences (OR=0.49, p=0.037)**


Randomized comparison of IVUS vs OCT-guided stenting with blinded cross-over imaging (n=70) showed that IVUS was superior and indicating that there is a need for a new paradigm for OCT-guided stenting

	IVUS	OCT	P-value
Final inflation pressure, atm	16.1±4.7	13.5±3.4	0.03
Final balloon diameter, mm	3.2±0.4	3.4±0.6	0.3
Proximal edge			
Plaque burden, %	37.1±10.1	45.7±10.9	0.001
Plaque burden >50%	8.6%	31.4%	0.04
MSA, mm <sup>2</sup>	7.1±2.1	6.1±2.2	0.04
Focal expansion	80±13%	65±14%	0.001
Distal edge			
Plaque burden, %	33.3±6.4	40.3±8.8	<0.001
Plaque burden >50%	2.9%	11.4%	0.4

***All OCT findings including the frequency of stent malapposition and the percentage of cross sections with malapposed struts were not significantly different between the groups.***


# Near Infrared Spectroscopy

## Interventional Role and Emerging Data






The culprit segments contained lipid rich plaque in 19 of 20 STEMI cases (95%), all with a large plaque burden.



IVUS and NIRS were performed pre-PCI in 20 STEMI pts. Culprit lesions were compared to nonculprit segments in the same artery and to autopsy control segments.


	STEMI Culprit	STEMI Non-culprit	Histology
#	20	87	279
MaxLCBI <sub>4mm</sub>	524 (445, 821)	90 (6, 265)	6 (0, 88)
Plaque burden (%)	64±14	44±15	44±14
Calcification (%)	89	38	0



# COLOR Registry

62 pts were studied pre-PCI using NIRS.  
Peri-procedure MI (cTnI >3x normal)  
occurred in 9 pts.

Predictors	RR	p
maxLCBI <sub>4mm</sub> >500	12.0	0.0002
LDL >100mg/dL	5.4	0.03
Angiographic complex lesion	3.5	0.15
Angiographic DS >75%	3.1	0.14



Peri-procedural MI - defined as an elevation >5× the ULN for either CPK-MB or Troponin I occurred in 21.6% of 88 pts with normal baseline biomarkers

- No differences in clinical or angiographic variables
- The best cut-off of maxLCBI<sub>4mm</sub> for detecting peri-procedural MI was 524 (AUC=0.672) with a specificity of 63% and a sensitivity of 78%.
- Peri-procedural MI occurred in 17 of 69 pts (24.6%) with maxLCBI<sub>4mm</sub> <500 compared with 12 of 19 pts (63.2%) with maxLCBI<sub>4mm</sub> ≥500 (p=0.002). The relative risk of peri-procedural MI for pts with maxLCBI<sub>4mm</sub> ≥500 was 5.2 (95% CI 1.8 to 16.2, p=0.002).

Goldstein et al. Circ Cardiovasc Interv 2011;4:429-437

Dohi et al. ACC2014

# Near Infrared Spectroscopy

## Interventional Role and Emerging Data

- 1. Vulnerable Plaque: ACS/STEMI**
- 2. Distal Embolization: COLOR registry, CANARY Study**
- 3. Stent Thrombosis**
- 4. Drug Evaluation: YELLOW trial**

Madder RD et al. JACC Cardiovascular Interv 2013;6:838-46

Madder RD et al. Circ Cardiovasc Interv 2012;5:55-61

Goldstein JA et al. Circ Cardiovasc Interv. 2011;4:429-437

Sakhuja R et al. Circulation 2010;122:2349-2350

Kini A et al. JACC 2013; 62: 21-9



# Echo Attenuated Plaque

## New Signals About Plaque Instability


### IVUS

Attenuated Plaque  
(Deep)

Attenuated Plaque  
(Deep)

Attenuated Plaque  
(Superficial)

Attenuated Plaque  
(Superficial)



### Pathology

PIT  
(Lipid pool)


Early FA  
(Early NC)

Late FA  
(Late NC)

TCFA  
(Late NC)

# Echo Attenuated Plaque

IVUS findings and Pathological Lipid/Necrotic Core



# Discussion

- Risk Prediction Based on Intracoronary Imaging
- OCT Guided PCI
- Clinical Roles of NIRS
- Echo-Attenuated Plaque
- Future Perspective of Intracoronary Imaging